Results 121 to 130 of about 3,814,825 (281)

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

Antiplatelet Agents: A Review [PDF]

Journal of the Royal Society of Medicine, 1979
openaire   +2 more sources

Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes

Patient Related Outcome Measures, 2010
Hussam M Tayeb, Adam J Nelson, Scott R Willoughby, Matthew I WorthleyCardiovascular Research Centre, Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, AustraliaAbstract: Platelets play a central role ...
Hussam M Tayeb, Adam J Nelson, Scott R Willoughby, et al   +3 more
doaj  

Effect of antiplatelet agents on Escherichia coli sepsis mechanisms: A review. [PDF]

Front Microbiol, 2022
Mariotti A, Ezzraimi AE, Camoin-Jau L.
europepmc   +1 more source

De‐Implementing Low‐Value Care in Dentistry: The Case for Choosing Wisely Campaigns

Community Dentistry and Oral Epidemiology, EarlyView.
ABSTRACT De‐implementation refers to the practice within implementation science that targets reducing low‐value care; that is practices that have been proven to be outdated, unnecessary, potentially harmful and in some cases not cost‐efficient. Reducing and removing habitual practices, as well as introducing new care, is not easy, as there are multiple
Fabio Arriola‐Pacheco, Rafael Aiello Bomfim, Karen Born, Herenia P. Lawrence   +3 more
wiley   +1 more source

Synthesis and Biological Evaluation of Novel Thiadiazole Derivatives as Antiplatelet Agents. [PDF]

Iran J Pharm Res, 2023
Khakpash M, Esfahanizadeh M, Mahboubi-Rabbani M, Amidi S, Kobarfard F.   +4 more
europepmc   +1 more source

Garadacimab for the long‐term prophylaxis of hereditary angioedema

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments.
Emel Aygören‐Pürsün, Regina Treudler, Petra Staubach, Inmaculada Martinez Saguer, Thomas Linhoff, Markus Magerl   +5 more
wiley   +1 more source

Preparation and Evaluation of 6-Gingerol Derivatives as Novel Antioxidants and Antiplatelet Agents. [PDF]

Antioxidants (Basel), 2023
Ahmed SHH, Gonda T, Agbadua OG, Girst G, Berkecz R, Kúsz N, Tsai MC, Wu CC, Balogh GT, Hunyadi A.   +9 more
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents. [PDF]

Clin Obstet Gynecol, 2023
James AH, Sugrue R, Federspiel JJ.
europepmc   +1 more source